Publication: Ensuring a Consistent Supply of Anthrax Vaccine
Loading...
Open/View Files
Date
2002
Authors
Published Version
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Ensuring a Consistent Supply of Anthrax Vaccine (2002 Third Year Paper)
Abstract
During the recent anthrax attacks, the country's supply of anthrax vaccine was dangerously low. The reasons for this were (1) the failure of the FDA, the Defense Department, and its contractor, BioPort Corporation, to plan adequately to ensure the production of a consistent supply of the vaccine in accordance with the FDA regulatory process; and (2) the reliance of the Defense Department on a single private supplier of the vaccine with serious financial problems. Careful planning should be employed to prevent such a situation with other biological products which may be needed to save lives during bioterrorist attacks.
Description
Other Available Sources
Research Data
Keywords
Food and Drug Law, vaccine,, anthrax,, FDA,, defense,, biologics
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service